Intellia Therapeutics Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Intellia Therapeutics han disminuido a una tasa media anual de -38.8%, mientras que en la industria Biotechs los beneficios crecieron en un 12.7% anualmente. Los ingresos han ido creciendo a una tasa media de 4.2% al año.

Información clave

-38.8%

Tasa de crecimiento de los beneficios

-26.3%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	4.2%
Rentabilidad financiera	-45.8%
Margen neto	-1,326.5%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Intellia Therapeutics Is On The Move

Feb 29

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 24

Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier

Feb 09

Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?

Feb 07

Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?

Jan 01

Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans

Oct 20

Intellia Therapeutics: Top Speculative Trade In The Biotech Space

Oct 05

Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling

Sep 01

Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022

Feb 09

Intellia: Best All-Around Gene Editing Company

Jan 27

We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth

Dec 31

Intellia Has Potential As Gene Therapy Play With Second Product Being Tested In Humans

Dec 15

Intellia Stock: Setting Up For Success

Nov 29

Intellia: A Step Closer To A Life-Changing Cure

Nov 21

Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Intrinsic Value Is Potentially 79% Above Its Share Price

Oct 11

Intellia's Data Has Underlined Huge Potential Of Gene Therapeutics And There Will Be More Soon

Aug 31

Here's Why We're Not At All Concerned With Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Situation

Aug 01

Estimating The Intrinsic Value Of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Jul 05

Intellia Makes History. Can It Deliver A Cure?

Jun 28

Intellia Therapeutics Q1 2021 Earnings Preview

May 05

Intellia Expands Its In Vivo Advantage

May 02

Companies Like Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Invest In Growth

Apr 16

Broker Revenue Forecasts For Intellia Therapeutics, Inc. (NASDAQ:NTLA) Are Surging Higher

Mar 12

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Intellia Therapeutics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGM:NTLA Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Dec 23	36	-481	116
30 Sep 23	52	-462	111
30 Jun 23	53	-453	104
31 Mar 23	53	-430	95
31 Dec 22	52	-474	90
30 Sep 22	51	-442	89
30 Jun 22	45	-400	85
31 Mar 22	38	-369	80
31 Dec 21	33	-268	71
30 Sep 21	27	-229	60
30 Jun 21	42	-185	52
31 Mar 21	52	-149	46
31 Dec 20	58	-134	44
30 Sep 20	62	-120	42
30 Jun 20	51	-116	40
31 Mar 20	46	-109	42
31 Dec 19	43	-100	41
30 Sep 19	40	-90	41
30 Jun 19	37	-89	41
31 Mar 19	33	-86	35
31 Dec 18	30	-85	32
30 Sep 18	29	-90	34
30 Jun 18	29	-83	31
31 Mar 18	27	-76	30
31 Dec 17	26	-68	28
30 Sep 17	25	-54	23
30 Jun 17	23	-46	22
31 Mar 17	21	-38	19
31 Dec 16	16	-32	17
30 Sep 16	13	-26	14
30 Jun 16	9	-22	11
31 Mar 16	7	-18	10
31 Dec 15	6	-12	8
30 Sep 15	4	-14	8

Ingresos de calidad: NTLA actualmente no es rentable.

Margen de beneficios creciente: NTLA actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: NTLA no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 38.8% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de NTLA en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: NTLA no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-8.9%).

Rentabilidad financiera

Alta ROE: NTLA tiene una rentabilidad financiera negativa (-45.82%), ya que actualmente no es rentable.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Intellia Therapeutics Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Intellia Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Intellia Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Third quarter 2023 earnings: EPS exceeds analyst expectations

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2023 earnings released: US$1.18 loss per share (vs US$1.97 loss in 1Q 2022)

Recent updates

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 3 MAGNITUDE Study of NTLA-2001 as Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy

Intellia Therapeutics Is On The Move

Intellia Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $375.727167 million.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

New major risk - Revenue and earnings growth

Intellia Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Intellia Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier

Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

President recently sold US$566k worth of stock

Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?

Independent Director notifies of intention to sell stock

Intellia Therapeutics, Inc. Announces Resignation of John F. Crowley from the Board of Directors of Company and Its Committees

Third quarter 2023 earnings: EPS exceeds analyst expectations

Intellia Therapeutics, Inc. Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 At the 4th International ATTR Amyloidosis Meeting

Insufficient new directors

Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Intellia Therapeutics, Inc. Appoints Eliana Clark, Phd, Executive Vice President and Chief Technical Officer

Intellia Therapeutics, Inc. Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)

Intellia Therapeutics, Inc. Announces Resignation of Jean-François Formela as Board Member

First quarter 2023 earnings released: US$1.18 loss per share (vs US$1.97 loss in 1Q 2022)

Price target decreased by 7.1% to US$96.27

Full year 2022 earnings released: US$6.16 loss per share (vs US$3.78 loss in FY 2021)

Executive VP & Chief Scientific Officer notifies of intention to sell stock

President recently sold US$248k worth of stock

Intellia Therapeutics Presents New Interim Data from First-In-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001

Third quarter 2022 earnings released: US$1.49 loss per share (vs US$0.97 loss in 3Q 2021)

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting

Intellia Therapeutics: Top Speculative Trade In The Biotech Space

Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

Intellia Therapeutics, Inc. Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema

Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling

Intellia Therapeutics, Inc. to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema At the 2022 Bradykinin Symposium

Consensus forecasts updated

Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Intellia Therapeutics down 12% following bottom line Q2 earnings miss

Intellia: Slim Hopes Of Near-Term Commercial Revenue Makes Me Bearish

Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Announces Additional Positive Interim Data from an Ongoing Phase 1 Study of Their Lead Investigational in Vivo Genome Editing Candidate, NTLA-2001

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022

Intellia Therapeutics: Several Catalysts Expected For H2 2022

Consensus forecasts updated

Price target decreased to US$137

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Intellia Therapeutics, Inc. Names Muna Bhanji to Its Board of Directors

Intellia Therapeutics, Inc., Annual General Meeting, Jun 14, 2022

Price target decreased to US$155

Intellia: One Patent Ruling Turns The Industry Upside Down

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for Treatment of Acute Myeloid Leukemia

Consensus forecasts updated

Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Intellia Therapeutics: A Lot Of News Can Bring The Stock Up

Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022

Intellia Therapeutics, Inc. (NasdaqGM : NTLA) acquired Rewrite Therapeutics, Inc. for $200 million.

Intellia: Best All-Around Gene Editing Company

We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth

Intellia Has Potential As Gene Therapy Play With Second Product Being Tested In Humans

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

Intellia Stock: Setting Up For Success

Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy

Intellia: A Step Closer To A Life-Changing Cure

Executive VP & Chief Medical Officer exercised options and sold US$288k worth of stock

Desglose de ingresos y gastos
Beta